The 3rd ISCC

December 3, 1998
Nagai Memorial Hall

Program

9:00-9:05

Haruo Sugano (Cancer Chemotherapy Center, Japan)

Welcome and Introduction

1. New Strategy for Drug Discovery

Chairperson: Edward A. Sausville (National Cancer Institute, USA)

William G. Kaelin, Jr. (Howard Hughes Medical Institute, USA)

Choosing drug targets in the post-genomic era

2. Angiogenesis Inhibitors and Antimetastatic Agents

Chairpersons: Jean P. Armand (Institut Gustave-Roussy, France)
Yutaka Ariyoshi (Aichi Hospital, Japan)

10:05-10:30

Michael S. O’Reilly (Children’s Hospital, Boston, USA)

Tumor dormancy by angiogenesis suppression

10:30-10:55

Laura K. Shawver (Sugen, Inc., USA)

Small molecule inhibitors of receptor tyrosine kinases for anti-angiogenic therapy

10:55-11:10

Kenya Shitara (Kyowa Hakko Kogyo, Co. Ltd., Japan?j

Anti-VEGF receptor neutralizing antibody

11:10-11:35

Henrik S. Rasmussen (British Biotech Inc., USA)

Matrix metalloproteinase inhibition with marimastat - a novel anticancer strategy

11:35-11:50

Motowo Nakajima (Novartis Pharma K.K., Japan)

Anti-metastatic effects of a matrix metalloproteinase inhibitor CGS27023A

3-1. New Interesting Drugs under Clinical Consideration (Part 1)

Chairpersons: Allen Oliff (Merck Research Laboratories, USA)
Takashi Tsuruo (University of Tokyo, Japan)

13:00-13:25

Allen Oliff (Merck Research Laboratories, USA)

Farnesyl transferase inhibitors as anticancer agents

13:25-13:50

Ivan D. Horak (Janssen Research Foundation, USA)

p21 Ras: A new target for therapeutic intervention

13:50-14:15

George R. P. Blackledge (Zeneca Pharmaceuticals, UK)

Clinical progress with the EGF receptor tyrosine kinase inhibitor, ZD1839

14:15-14:40

Alison Hannah (Sugen, Inc., USA)

SU101 - A novel signal transduction inhibitor and its effects on patients with a variety of tumors

14:40-14:55

Takao Yamori (Cancer Chemotherapy Center, Japan)

A novel DNA minor groove binder, MS-247: antitumor activity evaluated by in vitro and in vivo human cancer cell line panel

14:55-15:10

Manabu Suzuki (Ajinomoto, Co. Inc., Japan)

AC-7700, a novel combretastatin derivative, exerts strong antitumor effects through the selective decrease in tumor perfusion

15:10-15:25

Koji Murakami (Taiho Pharmaceutical, Co. Ltd., Japan)

Anti-tumor activity of TAC-101 against liver cancers and its mechanism of action

15:25-15:40

Discussion

15:40-16:10

Coffee Break

3-2. New Interesting Drugs under Clinical Consideration (Part 2)

Chairpersons: Michael S. O’Reilly (Dana Farber Cancer Center, USA)
Noboru Horikoshi (Cancer Chemotherapy Center, Japan)

16:10-16:25

Noriyuki Masuda (Osaka Prefectural Habikino Hospital, Japan)

Overview of preclinical and clinical studies of Amrubicin

16:25-16:40

Tomohide Tamura (National Cancer Center Hospital, Japan)

Clinical trial of DX8951f

16:40-16:55

Nagahiro Saijo (National Cancer Center Hospital, Japan)

A topoisomerase II targetting new drug, NK109

16:55-17:20

Ross Donehower (Johns Hopkins Oncology Center, USA)

Phase I trials in the U.S. of TAS-103 and CS-682

17:20-17:35

Discussion

4. Current Status in New Drug Development in the US and Europe

Chairpersons: Ross Donehower (Johns Hopkins Oncology Center, USA)
Haruo Sugano (Cancer Chemotherapy Center, Japan)

17:35-18:00

Edward A. Sausville (National Cancer Institute, USA)

New drugs at the NCI

18:00-18:25

Jean P. Armand (Institut Gustave-Roussy, France)

New drugs in France and Europe

18:25-18:30

Takashi Tsuruo (University of Tokyo, Japan)

Closing Remark

18:30-19:30

Mixer

Page TOP